Form 4: Neurocrine Biosciences Executive Sells Shares
Insider Transaction (Form 4)
Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc, sold 2,154 shares of common stock on September 9, 2026 for $154.61 per share.
Summary
- Option exercise/conversion: acquired 3,194 Common Stock at $43.24 ($138,109) on September 9, 2026; holds 66,562 after (Direct).
- Open-market sale: disposed of 2,154 Common Stock at $154.61 ($333,030) on September 9, 2026; holds 64,408 after (Direct).
- Option exercise/conversion: disposed of 3,194 Incentive Stock Option on September 9, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $333,030 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Eric Benevich — Officer (Chief Commercial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Option exercise/conversion | Common Stock | 3,194 | $43 | $138.1K | 66,562 |
| 2026-09-09 | Open-market sale | Common Stock | 2,154 | $155 | $333.0K | 64,408 |
| 2026-09-09 | Option exercise/conversion | Incentive Stock Option | 3,194 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Option exercise/conversion (3,194 shares) |
| 2026-09-09 | Open-market sale (2,154 shares) |
| 2026-09-09 | Option exercise/conversion (3,194 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, bearish, Eric Benevich
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.